



## RESULTS

For the six months ended 30th June 2002, the unaudited turnover of INNOMAXX Biotechnology Group Limited (the "Company") and its subsidiary companies (collectively "the Group") increased by 88.7% to approximately HK\$27,610,000 as compared to the corresponding period for 2001. The increase in turnover is mainly due to the sales of investment properties of HK\$19,200,000 during the period. Other major income of the Group includes the rental income from the shopping mall in PRC and the processing and storage fees of cord blood business. During 2002, the Group has not traded in securities. On the other hand, due to the loss of HK\$11,742,000 on the sales of investment properties during the period and the increase in the administrative expenses, the Group recorded a loss attributable to shareholders of approximately HK\$19,604,000 for the period under review (2001: HK\$4,548,000).